Amferia funding news – Sweden-based Amferia Secures €1.2Million in Funding

Chalmers Ventures, the investment arm of Chalmers University of Technology in Gothenburg, Sweden, led the €1.2 million financing round along with other new investors. It assists students, alumni, and businesses and spin-offs resulting from academic research.

This financial infusion will be essential to the development of Amferia's cutting-edge technology, which targets and eliminates bacteria—including those resistant to traditional antibiotics—using antimicrobial peptides. The investment is in line with Amferia's overarching objective of improving infection control worldwide, especially in light of the fact that antibiotic resistance continues to be a serious danger to public health.

Read also - BrowserStack Acquisition News – BrowserStack Acquires Bird Eats Bug, Launches Bug Capture to Accelerate Its Test Platform Vision

It has not only secured fresh finance but also inked its first business deal with Orkla Wound Care, a prominent player in the animal health industry. Through this collaboration, a ground-breaking wound covering for animals that kills resistant germs in addition to treating wounds will be introduced. This is a big step forward for Amferia since it allows it to use its patented hydrogel technology for purposes other than human health.

According to World Health Organization predictions, throughout the next ten years, wound-related antibiotic-resistant infections may rank among the most common causes of sickness and death. The hydrogel substance from Amferia is being researched further for potential use in deep wound sprays, implant coatings, and catheter varieties.

Anand Rajasekharan, CEO and co-founder of Amferia said, “Bacterial infections are likely to surpass cancer and heart disease as the number one cause of human deaths in the future, largely due to resistance to commonly used antibiotics, Our hydrogel technology enables the safe and stable use of antimicrobial peptides, allowing them to effectively target bacteria without harming surrounding tissue. Essentially, we are using antimicrobial peptides to mimic the immune system and reduce the need for antibiotics.”

Because of their positive electrostatic charge, which draws in negatively charged bacteria, antimicrobial peptides are well known for their capacity to eradicate germs. Because of this, the peptides are able to pierce bacterial membranes and kill the cells.

However, because these peptides are swiftly broken down by human body enzymes, their fragility in natural biological contexts presents a problem. The hydrogel from it provides a flexible solution that keeps the peptides safe from deterioration and guarantees their efficacy against even the most resilient bacteria.

Jonas Bergman, Investment Director at Chalmers Ventures said, “We believe this investment will help Amferia advance its hydrogel platform and bring it to the market for human use, A portion of the funds will be allocated towards regulatory and post-regulatory work for human use. It will also help Amferia form new strategic partnerships to ensure a smooth market entry.”

About Amferia

Swedish business Amferia AB creates and distributes innovative medical equipment, specializing in antibacterial goods. Amferia's main goal is to create materials that, when utilized as medical devices—such as wound care—can effectively destroy bacteria. Amferia is a spin-off from Chalmers University of Technology research.